PMID- 30534583
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2372-7705 (Print)
IS  - 2372-7705 (Electronic)
IS  - 2372-7705 (Linking)
VI  - 11
DP  - 2018 Dec 21
TI  - Recombinant Adenovirus KGHV500 and CIK Cells Codeliver Anti-p21-Ras scFv for the 
      Treatment of Gastric Cancer with Wild-Type Ras Overexpression.
PG  - 90-101
LID - 10.1016/j.omto.2018.10.003 [doi]
AB  - The development of gastric cancer is frequently related to the overexpression of 
      wild-type p21 proteins, but it is rarely related to mutated Ras proteins. We 
      previously constructed a broad-spectrum anti-p21-Ras single-chain variable 
      fragment antibody (scFv), which was carried by the oncolytic adenovirus KGHV500. 
      Here we explored the antitumor effects of this recombinant oncolytic adenovirus 
      carried by cytokine-induced killer (CIK) cells on human gastric SGC7901 cells 
      that overexpress wild-type Ras. The MTT assay, scratch test, Transwell assay, and 
      terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) 
      assay were performed in vitro to investigate the proliferation, migration, 
      invasiveness, and cell apoptosis rate, respectively, of the human gastric cell 
      line SGC7901 treated with KGHV500 adenovirus. Then, the tumor-targeting ability 
      and systemic safety of KGHV500 adenovirus delivered by CIK cells were explored 
      in vivo. We found that KGHV500 adenovirus could significantly inhibit 
      proliferation, migration, and invasiveness and promote cell apoptosis in SGC7901 
      cells in vitro. In vivo studies showed that CIK cells could successfully deliver 
      KGHV500 adenovirus to the tumor site; the two vectors synergistically killed 
      tumor cells, and the treatment was relatively safe for normal tissues. In 
      conclusion, this therapeutic strategy of recombinant adenovirus KGHV500 delivered 
      by CIK cells offers a positive prospect for the targeted therapy of Ras-related 
      cancers.
FAU - Wang, Mingjuan
AU  - Wang M
AD  - Kunming Medical University, Kunming, Yunnan Province, China.
FAU - Hong, Yanling
AU  - Hong Y
AD  - Kunming Medical University, Kunming, Yunnan Province, China.
FAU - Feng, Qiang
AU  - Feng Q
AD  - Department of Pathology, Kunming General Hospital, Kunming 650032, Yunnan 
      Province, China.
FAU - Pan, Xinyan
AU  - Pan X
AD  - Department of Pathology, Kunming General Hospital, Kunming 650032, Yunnan 
      Province, China.
FAU - Song, Shuling
AU  - Song S
AD  - Department of Pathology, Kunming General Hospital, Kunming 650032, Yunnan 
      Province, China.
FAU - Cui, Jing
AU  - Cui J
AD  - Department of Pathology, Kunming General Hospital, Kunming 650032, Yunnan 
      Province, China.
FAU - Lei, Jin
AU  - Lei J
AD  - Department of Pathology, Kunming General Hospital, Kunming 650032, Yunnan 
      Province, China.
FAU - Fang, Hong
AU  - Fang H
AD  - Department of Pathology, Kunming General Hospital, Kunming 650032, Yunnan 
      Province, China.
FAU - Yang, Julun
AU  - Yang J
AD  - Department of Pathology, Kunming General Hospital, Kunming 650032, Yunnan 
      Province, China.
LA  - eng
PT  - Journal Article
DEP - 20181023
PL  - United States
TA  - Mol Ther Oncolytics
JT  - Molecular therapy oncolytics
JID - 101666776
PMC - PMC6280635
OTO - NOTNLM
OT  - CIK cell
OT  - SGC7901
OT  - anti-p21-Ras
OT  - gastric cancer
OT  - oncolytic adenovirus
OT  - scFv
EDAT- 2018/12/12 06:00
MHDA- 2018/12/12 06:01
PMCR- 2018/10/23
CRDT- 2018/12/12 06:00
PHST- 2018/07/12 00:00 [received]
PHST- 2018/10/16 00:00 [accepted]
PHST- 2018/12/12 06:00 [entrez]
PHST- 2018/12/12 06:00 [pubmed]
PHST- 2018/12/12 06:01 [medline]
PHST- 2018/10/23 00:00 [pmc-release]
AID - S2372-7705(18)30027-5 [pii]
AID - 10.1016/j.omto.2018.10.003 [doi]
PST - epublish
SO  - Mol Ther Oncolytics. 2018 Oct 23;11:90-101. doi: 10.1016/j.omto.2018.10.003. 
      eCollection 2018 Dec 21.